Physician profile
Amanda Sells
NPI 1316244742
$3,663.05
in general payments reported to CMS, 2019-2025
23 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $155 · 2021: $324 · 2022: $376 · 2023: $832 · 2024: $988 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.03 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $433.60 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $312.78 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $310.65 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $292.02 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $185.08 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $184.18 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $181.46 | 2019-2025 | Austedo, Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $138.81 | 2019-2024 | |
| Corium, LLC | $137.20 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.53 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $97.59 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $61.67 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $59.74 | 2022-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $52.64 | 2023-2024 | Secuado, Xelstrym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $34.30 | 2019 | |
| Indivior INC. | $26.93 | 2020 | |
| Sunovion Pharmaceuticals INC. | $26.65 | 2019 | |
| Shire North American Group INC | $24.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.38 | 2025 | Cobenfy |
| Neuronetics, INC. | $20.74 | 2019 | |
| Collegium Pharmaceutical, INC. | $19.05 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.